Developing a Safer Approach to Treat Pain and Inflammation
At EicOsis we are advancing novel, safe and effective oral treatments for patients suffering from pain and inflammation.
Chronic pain affects 100 million Americans and causes a substantial physical and emotional impact on their lives. Current treatments for pain are insufficient, and patients are often prescribed opioids. Increased prescription of opioids has led to a widespread public health emergency, the US Opioid Crisis. There is an unmet need for safe, non-addictive and effective pain medications that can help pain patients and fight the US Opioid Crisis.
At EicOsis we are developing a new approach to treat pain and inflammation by inhibiting the soluble Epoxide Hydrolase (sEH), a key regulatory enzyme. Inhibiting sEH increases the levels of naturally occurring anti-inflammatory and pain-relieving compounds. Our first drug candidate is currently undergoing Phase 1 human clinical trials. Learn more about EicOsis Human Health.
June 2021: EicOsis has initiated a Phase 1 fed-fasted, single dose clinical trial of EC5026, our oral drug candidate for the treatment of pain. This trial comes after a successful single-ascending dose clinical trial with no drug-related adverse events in healthy volunteers.
Distinguished professor and EicOsis founder Dr. Bruce Hammock is part of the Who’s Who “click-chemistry team” that won the Royal Society of Chemistry’s Horizon Team Award for advancing chemistry and “pushing the boundaries of science.” The Horizon Prizes “highlight the most exciting, contemporary chemical science at the cutting edge of research and innovation.” The Award was announced on June 2021.
In an article published in Frontiers of Physiology, Dr. Cindy McReynolds and colleagues show how certain fatty acids in the blood of COVID-19 patients may predict severity. The compounds, known as leukotoxins and leukotoxin diols, originate from linoleic acid, the most abundant dietary fat. This discovery may offer a target for treatment.
An article published in Science Translational Medicine shows how an sEH inhibitor can reduce neuroinflammation in a mouse model of Alzheimer’s disease, making sEH inhibitors an attractive drug class for further development as potential treatment for Alzheimer’s disease.
The 14th Annual Pain Therapeutics Summit, who’s Chairperson is EicOsis’s Vicepresident for Clinical Development William Schmidt, took place virtually in November 2020. Leading figures across academia, industry and the public sector gathered to focus on identifying and advancing novel pain drugs through clinical development and commercialization. Next year’s summit is scheduled for November 1-2, 2021 in Washington, DC.
Dr. Hammock, Distinguished Professor in the Department of Entomology and Nematology at UC Davis, received the UC Davis Chancellor Lifetime Achievement Award in Innovation in June 2020. This award recognizes researchers whose career accomplishments include innovations leading to a long-term positive impact on the lives of others and who are an inspiring influence for other innovators.
EicOsis is advancing its first drug candidate to human clinical trials with the support of funding from federal grants and angel investors.
February, 2021 – Veterans Affairs investigator recibes Spinal Cord Injury Research Program (SCIRP) Clinical Trial Award from the Department of Defense to conduct clinical trial of EC5026 for neuropathic pain
October, 2019 – EicOsis receives SBIR grant award from NCI/NIH
October, 2019 – EicOsis receives $15 M from NIDA/NIH as part of the HEAL Initiative
March, 2019 – EicOsis raises funding for Phase 1 clinical development from Open Philanthropy
January, 2019 – EicOsis receives $4 M from NIH Blueprint for Neuroscience Research to advance oral analgesic to Phase 1 clinical trials for neuropathic pain
Learn more about our funding sources.